Table 2: Effects of tulobuterol and PDW on pulmonary function, quality of life, and hs-CRP.
Variables |
Tulobuterol (n = 13) |
PDW (n = 10) |
||
Pre |
Post |
Pre |
Post |
|
Pulmonary function |
||||
FVC (l) |
2.29 ± 0.60 |
2.38 ± 0.50 |
2.30 ± 0.50 |
2.40 ± 0.47* |
FEV1 (l) |
1.48 ± 0.38 |
1.53 ± 0.35 |
1.46 ± 0.34 |
1.56 ± 0.32* |
FEV1 %pred (%) |
82.07 ± 17.3 |
86.05 ± 14.2 |
80.49 ± 14.3 |
86.00 ± 11.6* |
PEF (l/s) |
4.05 ± 1.53 |
4.30 ± 1.41 |
3.93 ± 1.57 |
4.56 ± 1.64* |
MEF50 (l/s) |
1.23 ± 0.42 |
1.42 ± 0.62 |
1.22 ± 0.44 |
1.36 ± 0.44* |
MEF25 (l/s) |
0.40 ± 0.13 |
0.41 ± 0.15 |
0.39 ± 0.14 |
0.43 ± 0.14* |
SGRQ domain scores |
||||
Symptoms |
54.30 ± 22.48 |
54.16 ± 20.40 |
47.07 ± 21.59 |
51.58 ± 24.02 |
Activity |
42.38 ± 24.43 |
48.83 ± 25.46* |
41.22 ± 20.81 |
52.85 ± 21.98* |
Impacts |
23.89 ± 16.04 |
25.56 ± 15.32 |
23.54 ± 13.95 |
25.51 ± 16.27 |
Total |
35.72 ± 17.93 |
37.71 ± 16.57 |
33.98 ± 15.94 |
37.71 ± 16.79 |
Hs-CRP (ng/ml) |
1279 ± 2713 |
2521 ± 7986 |
685 ± 697 |
839 ± 947 |
Abbreviations: FEV1: Forced Expiratory Volume in 1.0 s; FVC: Forced Vital Capacity; PEF: Peak Expiratory Flow; MEF50: Maximum Expiratory Flow at 50% of FVC; MEF25: Maximum Expiratory Flow at 25% of FVC;
Hs-CRP: Hypersensitive-C-Reactive Protein.
Data are expressed as the mean ± SD.